FDA clearance for Medtronic’s LigaSure RAS Maryland instrument adds a familiar vessel-sealing technology to Hugo, strengthening the company’s effort to build a broader robotic surgery ecosystem around instruments, procedures and recurring revenue.
The FDA has issued an early alert involving certain Medtronic and Given Imaging Bravo CF esophageal pH capsule delivery devices after reports of 184 serious injuries linked to deployment failures that can lead to aspiration, perforation, airway obstruction and bleeding.
Medtronic has secured an expanded European CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 catheter, allowing the platform to treat ventricular arrhythmias including ventricular tachycardia and premature ventricular complexes. The August 6, 2026 regulatory expansion moves Sphere-9 beyond the atrial arrhythmias for which the system was initially commercialized. Medtronic describes
Momentis Surgical wins FDA clearance for Anovo multiport surgery, widening its robotic platform while adoption and evidence remain key.
SurGenTec’s ION-L gains FDA-cleared StealthStation navigation compatibility, but adoption will depend on clinical proof and operating-room economics.
Johnson & Johnson can launch its table-integrated Ottava surgical robot in the United States, opening a new competitive front against Intuitive Surgical and Medtronic.
CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Boston Scientific owns the PFA market. Pulse Biosciences just posted 90% one-year AF freedom. Is nanosecond PFA a real disruption or an acquisition target?
SurGenTec won FDA 510(k) clearance for TiLink navigation instruments. Read what this means for SI joint fusion adoption, workflow, and competition.